期刊
JOURNAL OF CONTROLLED RELEASE
卷 140, 期 2, 页码 79-85出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2009.08.014
关键词
Docetaxel; Chitosan; Conjugate; Oral delivery; Anticancer therapy
资金
- Cell Dynamics Research Center, Korean Ministry of Science and Technology [R1-2007-007-03002-0]
- Korea Healthcare Technology R&D Project, Ministry for Health, Welfare Family Affairs [A084764]
- Korea Health Promotion Institute [A084764] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [과06A1202] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The purpose of this study is to evaluate in vivo antitumor efficacy and subacute toxicity of docetaxel (DTX) prodrug comprising a conjugate between DTX and low molecular weight chitosan (LMWC) after oral administration. DTX was covalently attached to LMWC via a cleavable linker so as to be released from LMWC-DTX conjugate in body. In vitro cytotoxicity of LMWC-DTX conjugate was evaluated by MTT assay against two human cancer cell lines, showing similar IC50 values to the parent DTX. The pharmacokinetic data of the conjugate after oral administration revealed that half-life in blood circulation was increased by similar to 15-fold and AUC((0-infinity)) was 3.8-6.2 times higher in comparison with the intravenously injected DTX (i.v.). In vivo antitumor efficacy was evaluated in nude mice bearing human non-small cell lung carcinoma (NCI-H358) and glioblastoma (U87MG), respectively. The orally administered LMWC-DTX conjugate (10 mg DUX equivalent/kg) showed comparable antitumor efficacy to the same dose of DTX (i.v.) for both NCI-H358 and U87MG models, but revealed much lower subacute toxicity as seen in body weight loss and hematological toxicity. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据